Should Mucomyst Be Held Prior to Hip Surgery?
No, N-acetylcysteine (Mucomyst) should not be held prior to hip surgery in patients with chronic bronchitis or COPD who are taking it for chronic prevention of exacerbations. There is no evidence that continuing this medication increases surgical risk, and abrupt discontinuation may precipitate respiratory complications in patients who depend on it for airway clearance and exacerbation prevention.
Rationale for Continuing N-Acetylcysteine
No Contraindication in Perioperative Guidelines
The 2021 Association of Anaesthetists guideline for hip fracture management provides comprehensive recommendations for perioperative medication management but does not list N-acetylcysteine among medications that should be stopped before surgery 1.
The guideline specifically addresses which medications to hold (NSAIDs, aminoglycosides, amphotericin B, metformin) but makes no mention of mucolytics or N-acetylcysteine requiring discontinuation 2.
Therapeutic Role in COPD Patients
N-acetylcysteine is indicated for patients with chronic bronchopulmonary disease including chronic emphysema, emphysema with bronchitis, and chronic asthmatic bronchitis, as well as pulmonary complications associated with surgery and use during anesthesia 3.
The American College of Chest Physicians recommends N-acetylcysteine 600 mg twice daily for chronic prevention of exacerbations in patients with moderate to severe COPD who have experienced ≥2 exacerbations in the previous 2 years 4.
High-dose N-acetylcysteine (≥1200 mg daily) reduces annual exacerbation rates (relative risk 0.78) and requires at least 6 months of continuous therapy for benefits to become significant 4, 5.
Perioperative Considerations
Potential Benefits During Surgery
The FDA label explicitly lists "pulmonary complications associated with surgery" and "use during anesthesia" as indications for N-acetylcysteine 3.
N-acetylcysteine reduces viscosity of respiratory secretions through cleavage of disulfide bonds in mucoproteins, which may be particularly beneficial in the perioperative period when patients have reduced mobility and impaired cough 4.
Renal Protection Considerations
The 2025 EACTS/EACTAIC/EBCP guidelines on cardiopulmonary bypass note that perioperative intravenous N-acetylcysteine may be considered in patients with chronic kidney disease to reduce acute kidney injury after cardiac surgery (Class IIb recommendation, Level B evidence) 6.
While this evidence is from cardiac surgery, it suggests N-acetylcysteine has potential protective effects rather than harmful ones in the surgical setting 6.
Clinical Algorithm for Decision-Making
Patients Currently Taking Chronic N-Acetylcysteine
Continue the medication through the perioperative period at the patient's usual dose (typically 600 mg twice daily) 4.
Resume oral intake as soon as possible postoperatively to maintain therapeutic levels 4.
Consider temporary conversion to nebulized formulation only if the patient cannot take oral medications for an extended period, though oral administration is preferred 7.
Important Caveats
Do not confuse with acute exacerbation treatment: N-acetylcysteine is recommended against during acute COPD exacerbations but is beneficial for chronic prevention 4.
Distinguish from tranexamic acid: The hip fracture guideline warns that tranexamic acid should not be drawn up until after spinal anesthesia to avoid inadvertent intrathecal administration, but this caution does not apply to N-acetylcysteine 1.
Monitor for bronchospasm: If nebulized N-acetylcysteine is used perioperatively, pre-treatment with a short-acting β-agonist is advised to reduce bronchospasm risk 4.
Patients Not Currently on N-Acetylcysteine
Do not initiate N-acetylcysteine solely for perioperative prophylaxis in hip surgery patients, as there is insufficient evidence for this indication 8, 9.
Benefits of N-acetylcysteine require prolonged therapy (≥6 months) to manifest, making acute perioperative initiation ineffective 4.
Common Pitfalls to Avoid
Mistaking chronic prevention for acute treatment: N-acetylcysteine is effective for chronic exacerbation prevention but not recommended during acute exacerbations; ensure the patient is on stable chronic therapy, not acute treatment 4.
Unnecessary discontinuation: There is no evidence that continuing N-acetylcysteine increases bleeding risk, interferes with anesthesia, or causes other perioperative complications 1, 3.
Confusing with anticoagulants: Unlike warfarin or DOACs, N-acetylcysteine does not require specific timing adjustments or reversal strategies before neuraxial anesthesia 1.